SI1248804T2 - Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta - Google Patents

Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta

Info

Publication number
SI1248804T2
SI1248804T2 SI200130698T SI200130698T SI1248804T2 SI 1248804 T2 SI1248804 T2 SI 1248804T2 SI 200130698 T SI200130698 T SI 200130698T SI 200130698 T SI200130698 T SI 200130698T SI 1248804 T2 SI1248804 T2 SI 1248804T2
Authority
SI
Slovenia
Prior art keywords
beta
recombinant antibodies
human interleukin
interleukin
human
Prior art date
Application number
SI200130698T
Other languages
English (en)
Slovenian (sl)
Other versions
SI1248804T1 (sl
Inventor
Hermann Gram
Padova Franco E Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1248804(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1248804T1 publication Critical patent/SI1248804T1/sl
Publication of SI1248804T2 publication Critical patent/SI1248804T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
SI200130698T 2000-01-21 2001-01-19 Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta SI1248804T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
EP01905671A EP1248804B2 (fr) 2000-01-21 2001-01-19 Anticorps anti-interleukine 1-beta humain
PCT/EP2001/000591 WO2001053353A2 (fr) 2000-01-21 2001-01-19 Anticorps anti-interleukine 1$g(b) humain

Publications (2)

Publication Number Publication Date
SI1248804T1 SI1248804T1 (sl) 2007-06-30
SI1248804T2 true SI1248804T2 (sl) 2010-04-30

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130698T SI1248804T2 (sl) 2000-01-21 2001-01-19 Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta

Country Status (33)

Country Link
US (4) US20030124617A1 (fr)
EP (1) EP1248804B2 (fr)
JP (2) JP3978338B2 (fr)
KR (1) KR100697126B1 (fr)
CN (1) CN1395581B (fr)
AR (1) AR027253A1 (fr)
AT (1) ATE346868T1 (fr)
AU (1) AU772949B2 (fr)
BR (1) BR0107661A (fr)
CA (1) CA2396212C (fr)
CO (1) CO5261584A1 (fr)
CY (1) CY1107989T1 (fr)
CZ (1) CZ302738B6 (fr)
DE (1) DE60124863T3 (fr)
DK (1) DK1248804T4 (fr)
ES (1) ES2274865T5 (fr)
GB (1) GB0001448D0 (fr)
HK (1) HK1050013A1 (fr)
HU (1) HUP0204156A3 (fr)
IL (2) IL150551A0 (fr)
MX (1) MXPA02007091A (fr)
MY (1) MY155269A (fr)
NO (1) NO329816B1 (fr)
NZ (1) NZ519936A (fr)
PE (1) PE20011219A1 (fr)
PL (1) PL207642B1 (fr)
PT (1) PT1248804E (fr)
RU (1) RU2264413C2 (fr)
SI (1) SI1248804T2 (fr)
SK (1) SK288054B6 (fr)
TR (1) TR200201780T2 (fr)
WO (1) WO2001053353A2 (fr)
ZA (1) ZA200205659B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
CA2411374C (fr) 2000-06-29 2012-10-30 Abbott Laboratories Anticorps a double specificite, procedes de fabrication et d'utilisation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CN1652821A (zh) * 2002-01-28 2005-08-10 米德列斯公司 抗前列腺特异性膜抗原(psma)的人单克隆抗体
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
JP4711963B2 (ja) * 2003-09-15 2011-06-29 オクラホマ メディカル リサーチ ファウンデーション 炎症性疾患および自己免疫疾患を診断、治療および評価するためにサイトカインアッセイを用いる方法
PL1766093T3 (pl) * 2004-02-06 2011-11-30 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
CA2590164A1 (fr) 2005-01-26 2006-08-03 Amgen Fremont Inc. Anticorps diriges contre interleukine-1 beta
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
SI2314623T1 (sl) * 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
EP3332807B1 (fr) * 2005-10-26 2023-02-22 Novartis AG Utilisation d' anticorps anti il-1beta
ES2517420T3 (es) * 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
WO2007120828A1 (fr) * 2006-04-14 2007-10-25 Novartis Ag Utilisation d'anticorps anti-il-1 pour le traitement de troubles ophtalmiques
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
AU2007333635B2 (en) 2006-12-20 2014-02-20 Xoma (Us) Llc Treatment of IL-1-beta related diseases
EP2114443A4 (fr) * 2006-12-29 2011-08-10 Abbott Lab Anticorps il-1a/il-1b a double specificite
EP2417974A1 (fr) 2007-02-28 2012-02-15 Schering Corporation Polythérapie pour le traitement de maladies immunes
KR102606597B1 (ko) * 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
MX2010006823A (es) 2007-12-20 2010-09-30 Xoma Technology Ltd Metodos para el tratamiento de la gota.
EP2293816B1 (fr) * 2008-06-06 2012-11-07 XOMA Technology Ltd. Procédés pour le traitement de la polyarthrite rhumatoïde
CA2735939A1 (fr) 2008-09-05 2010-03-11 Xoma Technology Ltd. Procedes pour ameliorer la fonction des cellules beta
PL2493922T3 (pl) 2009-10-26 2017-07-31 F.Hoffmann-La Roche Ag Sposób wytwarzania glikozylowanych immunoglobulin
NZ603191A (en) 2010-05-07 2015-02-27 Xoma Technology Ltd Methods for the treatment of il-1b related conditions
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
JP6146913B2 (ja) 2010-08-02 2017-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｌドメインを含む結合タンパク質を作製するマウス
JP5866130B2 (ja) * 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
ES2748832T5 (es) 2011-02-25 2023-06-08 Regeneron Pharma Ratones ADAM6
EP3865581A1 (fr) 2011-08-05 2021-08-18 Regeneron Pharmaceuticals, Inc. Souris à chaîne légère universelle humanisée
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
WO2013096516A1 (fr) 2011-12-19 2013-06-27 Xoma Technology Ltd. Méthodes de traitement de l'acné
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
ES2798110T3 (es) 2012-02-13 2020-12-09 Agency Science Tech & Res Anticuerpos monoclonales humanos neutralizantes de IL-beta
SG11201407789RA (en) 2012-06-12 2014-12-30 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
EP3119194B1 (fr) 2014-03-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Animaux non humains qui produisent des protéines de liaison monodomaine
CA2941514A1 (fr) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Proteines de liaison a l'antigene vl presentant des caracteristiques de liaison distinctes
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
KR20210093973A (ko) 2018-11-20 2021-07-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (fr) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1248804A2 (fr) 2002-10-16
PL207642B1 (pl) 2011-01-31
DK1248804T3 (da) 2007-02-26
NZ519936A (en) 2004-02-27
KR100697126B1 (ko) 2007-03-20
US20110182894A1 (en) 2011-07-28
SK288054B6 (sk) 2013-03-01
PT1248804E (pt) 2007-02-28
AR027253A1 (es) 2003-03-19
KR20020073178A (ko) 2002-09-19
US20030124617A1 (en) 2003-07-03
CZ20022531A3 (cs) 2002-10-16
SI1248804T1 (sl) 2007-06-30
EP1248804B2 (fr) 2009-12-02
WO2001053353A3 (fr) 2002-04-04
DE60124863T2 (de) 2007-04-26
SK10352002A3 (sk) 2003-03-04
NO20023266D0 (no) 2002-07-05
WO2001053353A2 (fr) 2001-07-26
AU3369701A (en) 2001-07-31
ES2274865T3 (es) 2007-06-01
PE20011219A1 (es) 2001-12-17
BR0107661A (pt) 2002-11-19
CO5261584A1 (es) 2003-03-31
US20090232803A1 (en) 2009-09-17
HUP0204156A2 (hu) 2003-03-28
CY1107989T1 (el) 2013-09-04
US7491392B2 (en) 2009-02-17
ATE346868T1 (de) 2006-12-15
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
HK1050013A1 (zh) 2003-06-06
IL150551A0 (en) 2003-02-12
US20060251660A1 (en) 2006-11-09
ES2274865T5 (es) 2010-04-19
NO329816B1 (no) 2010-12-27
IL150551A (en) 2010-11-30
PL356297A1 (en) 2004-06-28
ZA200205659B (en) 2003-12-31
MY155269A (en) 2015-09-30
TR200201780T2 (tr) 2003-01-21
JP3978338B2 (ja) 2007-09-19
CA2396212A1 (fr) 2001-07-26
MXPA02007091A (es) 2002-12-13
DE60124863T3 (de) 2010-05-20
HUP0204156A3 (en) 2005-09-28
EP1248804B1 (fr) 2006-11-29
JP2003520595A (ja) 2003-07-08
CN1395581A (zh) 2003-02-05
CN1395581B (zh) 2010-10-13
RU2002121649A (ru) 2004-03-10
DK1248804T4 (da) 2010-04-06
JP2007097598A (ja) 2007-04-19
AU772949B2 (en) 2004-05-13
RU2264413C2 (ru) 2005-11-20
CA2396212C (fr) 2013-04-02
GB0001448D0 (en) 2000-03-08
NO20023266L (no) 2002-08-28

Similar Documents

Publication Publication Date Title
ZA200205659B (en) Recombinant antibodies to human interleukin-1 beta
NL300427I1 (en) Antibodies to human IL-1 beta
AU4835001A (en) Antibodies to human cd154
IL153721A0 (en) Antibodies to human mcp-1
HK1203521A1 (en) Antibodies to nsulin-like growth factor receptor
EP1156924A4 (fr) Structure a hautes performances
IL161705A0 (en) Human monoclonal antibodies to dendritic cells
IL185764A0 (en) Antibody to cytokine receptor zalpha11
EP1423432A4 (fr) Anticorps vis-a-vis de l'interleukine 1 beta (il-1beta)
EP1178829A4 (fr) Anticorps monoclonal humain
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
EP1151006A4 (fr) Recepteur couple de proteine g humaine
TW450361U (en) Egg collector for parasite egg in feces
HK1046793A1 (zh) 多路複用器結構
GB0011269D0 (en) Protein over expression
AU2001245815A1 (en) Human immune response proteins
TW390150U (en) Improved structure for hair-washing chair
EP1152059A4 (fr) Nouvelle proteine de type recepteur de cytokines
TW435091U (en) Underpants with dividing structure
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
IL126245A0 (en) Antibodies to ifn-beta2/il-6 receptor
GB0004695D0 (en) Protein expression
GB0027675D0 (en) Protein Expression
GB9902139D0 (en) Therapeutic non-autologous proteins